Sunday, November 27, 2016 12:31:22 PM
There are a few variations but most share some common features. The battery-powered exoskeleton will reduce strain on the body, conserve energy, provide better ballistic protection, and improve communication with other SOF Soldiers. Much of the technology already exists in various forms – they just need to be melded together into one complete package.
The Iron Man Suit is ideally suited for special operations soldiers engaged in high-risk operations such as entering and clearing buildings where terrorists may be harbored. The suit will provide additional protection needed – especially for the first man in the stack going through the door.
Tradeoffs. The capabilities of the suit will be limited by how much it weighs and the battery life of the suit. The heavier the suit the more energy required for it to function – which will decrease the battery life. Another limitation will be the flexibility of the suit – it must allow the operator to run, jump, bend, squat, and perform other physical feats required in combat operations.
http://www.sof.news/ussocom/talos-iron-man-suit/
I'm long ekso
Recent EKSO News
- Ekso Bionics Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/29/2024 08:05:00 PM
- Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024 • GlobeNewswire Inc. • 04/22/2024 12:00:00 PM
- Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal • GlobeNewswire Inc. • 04/12/2024 12:00:16 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/04/2024 09:14:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:08:54 PM
- Ekso Bionics Reports Record Annual Revenue of $18.3 Million • GlobeNewswire Inc. • 03/04/2024 09:05:00 PM
- Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024 • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 05:16:39 PM
- Ekso Bionics Announces $4.6 Million Registered Direct Offering • GlobeNewswire Inc. • 01/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 10:23:43 PM
- Ekso Bionics Launches GaitCoach Software for EksoNR • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 01/04/2024 10:05:12 PM
- Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Ekso Bionics to Participate at Centers for Medicare & Medicaid Services (CMS) Second Biannual 2023 Healthcare Common Procedure Coding System (HCPCS) Public Meeting on Wednesday, November 29 • GlobeNewswire Inc. • 11/16/2023 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:13:59 PM
- Centers for Medicare & Medicaid Services (CMS) Codifies Medicare Coverage for Ekso Indego Personal • GlobeNewswire Inc. • 11/02/2023 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/26/2023 08:17:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 08:10:19 PM
- Ekso Bionics Reports Third Quarter 2023 Revenue Growth of 38% • GlobeNewswire Inc. • 10/26/2023 08:05:00 PM
- Ekso Bionics to Report Third Quarter 2023 Financial Results on October 26, 2023 • GlobeNewswire Inc. • 10/19/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/29/2023 09:23:17 PM
- Ekso Bionics Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Include Personal Exoskeletons within a Medicare Benefit Category • GlobeNewswire Inc. • 09/27/2023 12:00:00 PM
- Ekso Bionics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/11/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2023 01:44:10 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM